GILEAD SCIENCES SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
Not Applicable
Terminated
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00158704
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
Phase 3
Completed
- Conditions
- Invasive AspergillosisOther Fungal Infections
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-11-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 800
- Registration Number
- NCT00158730
Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT00158717
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 274
- Registration Number
- NCT00128492
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: TDFDrug: ADV placeboDrug: ADVDrug: TDF placeboDrug: FTC/TDF
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 382
- Registration Number
- NCT00117676
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: TDFDrug: ADV placeboDrug: ADVDrug: FTC/TDFDrug: TDF placebo
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 266
- Registration Number
- NCT00116805
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Phase 2
Terminated
- Conditions
- Waldenstrom Macroglobulinemia
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT00113802
- Locations
- 🇺🇸
Weill Medical College of Cornell/ New York Presbyterian Hospital, New York, New York, United States
🇺🇸Columbia University College of Physicans & Surgeons, New York, New York, United States
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo three times a day (TID)Drug: AZLI 75 mg three times a day (TID)
- First Posted Date
- 2005-06-02
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 166
- Registration Number
- NCT00112359
- Locations
- 🇺🇸
Children's Memorial Hospital / Northwestern University, Chicago, Illinois, United States
🇺🇸University of Missouri, Columbia, Missouri, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Emtricitabine (FTC)Drug: Tenofovir Disoproxil Fumarate (TDF)Drug: Lamivudine/zidovudineDrug: Efavirenz (EFV)Drug: FTC/TDFDrug: FTC/TDF/EFV
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 517
- Registration Number
- NCT00112047
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸AIDS Healthcare Foundation Research, Beverly Hills, California, United States
🇺🇸Capital Medical Associates, P.C., Washington, District of Columbia, United States
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
Phase 4
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2005-03-24
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT00106379
- Locations
- 🇺🇸
Gary Richmond, MD, Fort Lauderdale, Florida, United States
🇺🇸Treasure Coast Infectious Disease Consultants, Vero Beach, Florida, United States
🇺🇸Fernando Garcia, MD, Harlingen, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath